Understanding the mechanisms of faecal microbiota transplantation

[1]  A. Khoruts,et al.  Inflammatory Bowel Disease Affects the Outcome of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[2]  A. Khoruts,et al.  Ursodeoxycholic Acid Inhibits Clostridium difficile Spore Germination and Vegetative Growth, and Prevents the Recurrence of Ileal Pouchitis Associated With the Infection , 2016, Journal of clinical gastroenterology.

[3]  Nitin Kumar,et al.  Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation , 2016, Nature.

[4]  F. Bushman,et al.  Transfer of Viral Communities between Human Individuals during Fecal Microbiota Transplantation , 2016, mBio.

[5]  A. Khoruts.  First microbial encounters , 2016, Nature Medicine.

[6]  M. Ouellette,et al.  Nisin is an effective inhibitor of Clostridium difficile vegetative cells and spore germination. , 2016, Journal of medical microbiology.

[7]  Ron Milo,et al.  Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans , 2016, Cell.

[8]  A. Khoruts,et al.  Changes in Colonic Bile Acid Composition following Fecal Microbiota Transplantation Are Sufficient to Control Clostridium difficile Germination and Growth , 2016, PloS one.

[9]  G. Russo,et al.  Long-term changes of bacterial and viral compositions in the intestine of a recovered Clostridium difficile patient after fecal microbiota transplantation , 2016, Cold Spring Harbor molecular case studies.

[10]  Ritu Shrestha,et al.  Reexamining the Germination Phenotypes of Several Clostridium difficile Strains Suggests Another Role for the CspC Germinant Receptor , 2015, Journal of bacteriology.

[11]  J. Garcia-Gil,et al.  Anti-tumour Necrosis Factor Treatment with Adalimumab Induces Changes in the Microbiota of Crohn's Disease. , 2015, Journal of Crohn's & colitis.

[12]  Samuel I. Miller,et al.  Low Level Engraftment and Improvement following a Single Colonoscopic Administration of Fecal Microbiota to Patients with Ulcerative Colitis , 2015, PloS one.

[13]  T. Borody,et al.  The Long-term Efficacy and Safety of Fecal Microbiota Transplant for Recurrent, Severe, and Complicated Clostridium difficile Infection in 146 Elderly Individuals , 2015, Journal of clinical gastroenterology.

[14]  R. Vuppalanchi,et al.  Faecal microbiota transplantation plus selected use of vancomycin for severe‐complicated Clostridium difficile infection: description of a protocol with high success rate , 2015, Alimentary pharmacology & therapeutics.

[15]  E. Zoetendal,et al.  Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. , 2015, Gastroenterology.

[16]  M. Surette,et al.  Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. , 2015, Gastroenterology.

[17]  E. Zoetendal,et al.  Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation , 2015, The American Journal of Gastroenterology.

[18]  V. Tremaroli,et al.  Dynamics and Stabilization of the Human Gut Microbiome during the First Year of Life. , 2015, Cell host & microbe.

[19]  Antonio Ramos,et al.  Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. , 2015, JAMA.

[20]  M. V. D. van den Brink,et al.  Interleukin-22: immunobiology and pathology. , 2015, Annual review of immunology.

[21]  J. M. Rodriguez,et al.  Loss of Vancomycin-Resistant Enterococcus Fecal Dominance in an Organ Transplant Patient With Clostridium difficile Colitis After Fecal Microbiota Transplant , 2015, Open forum infectious diseases.

[22]  Sophie J. Weiss,et al.  Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection , 2015, Microbiome.

[23]  W. Petri,et al.  Inflammasome Activation Contributes to Interleukin-23 Production in Response to Clostridium difficile , 2015, mBio.

[24]  J. Walters,et al.  The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid , 2015, Alimentary pharmacology & therapeutics.

[25]  G. Russell,et al.  Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. , 2014, JAMA.

[26]  Chris Sander,et al.  Precision microbiome restoration of bile acid-mediated resistance to Clostridium difficile , 2014, Nature.

[27]  G. Núñez,et al.  Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage. , 2014, Immunity.

[28]  James J Collins,et al.  Antibiotics and the gut microbiota. , 2014, The Journal of clinical investigation.

[29]  J. Bakken.  Staggered and tapered antibiotic withdrawal with administration of kefir for recurrent Clostridium difficile infection. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  Glenn R. Gibson,et al.  The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic , 2014 .

[31]  Daniel M. Saman,et al.  Recovery of the Gut Microbiome following Fecal Microbiota Transplantation , 2014, mBio.

[32]  Lin Li,et al.  Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome , 2014, Nature.

[33]  A. Kostic,et al.  The microbiome in inflammatory bowel disease: current status and the future ahead. , 2014, Gastroenterology.

[34]  A. Khoruts,et al.  Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation , 2014, Microbiome.

[35]  Y. Belkaid,et al.  Role of the Microbiota in Immunity and Inflammation , 2014, Cell.

[36]  Z. Kassam,et al.  The outcome and long-term follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[37]  S. Tims,et al.  Reset of a critically disturbed microbial ecosystem: faecal transplant in recurrent Clostridium difficile infection , 2014, The ISME Journal.

[38]  E. Alm,et al.  Policy: How to regulate faecal transplants , 2014, Nature.

[39]  A. Khoruts,et al.  Microbiota transplantation restores normal fecal bile acid composition in recurrent Clostridium difficile infection. , 2014, American journal of physiology. Gastrointestinal and liver physiology.

[40]  H. Goossens,et al.  Antibiotic resistance—the need for global solutions , 2013, BDJ.

[41]  Max Nieuwdorp,et al.  Therapeutic potential of fecal microbiota transplantation. , 2013, Gastroenterology.

[42]  M. Trauner,et al.  Temporal Bacterial Community Dynamics Vary Among Ulcerative Colitis Patients After Fecal Microbiota Transplantation , 2013, The American Journal of Gastroenterology.

[43]  W. Petri,et al.  Role of interleukin 23 signaling in Clostridium difficile colitis. , 2013, The Journal of infectious diseases.

[44]  W. Petritsch,et al.  Alteration of Intestinal Dysbiosis by Fecal Microbiota Transplantation Does not Induce Remission in Patients with Chronic Active Ulcerative Colitis , 2013, Inflammatory bowel diseases.

[45]  B. Weimer,et al.  Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens , 2013, Nature.

[46]  A. Khoruts,et al.  Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. , 2013, Journal of clinical gastroenterology.

[47]  Ritu Shrestha,et al.  Bile Acid Recognition by the Clostridium difficile Germinant Receptor, CspC, Is Important for Establishing Infection , 2013, PLoS pathogens.

[48]  P. Dürre,et al.  Clostridium difficile Is an Autotrophic Bacterial Pathogen , 2013, PloS one.

[49]  J. Walters,et al.  Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[50]  Elena Deych,et al.  Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  R. P. Ross,et al.  Prevalence and characterization of Clostridium perfringens from the faecal microbiota of elderly Irish subjects. , 2013, Journal of medical microbiology.

[52]  E. Zoetendal,et al.  Duodenal infusion of donor feces for recurrent Clostridium difficile. , 2013, The New England journal of medicine.

[53]  G. Gloor,et al.  Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut , 2013, Microbiome.

[54]  Matthew J. Hamilton,et al.  High-throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria , 2013, Gut microbes.

[55]  L. Brandt,et al.  Fecal microbiota transplantation: past, present and future , 2013, Current opinion in gastroenterology.

[56]  Taane G. Clark,et al.  Targeted Restoration of the Intestinal Microbiota with a Simple, Defined Bacteriotherapy Resolves Relapsing Clostridium difficile Disease in Mice , 2012, PLoS pathogens.

[57]  N. Socci,et al.  Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  G. Núñez,et al.  Protective Role of Commensals against Clostridium difficile Infection via an IL-1β–Mediated Positive-Feedback Loop , 2012, The Journal of Immunology.

[59]  Fernanda C. Lessa,et al.  Current Status of Clostridium difficile Infection Epidemiology , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  A. Khoruts,et al.  Standardized Frozen Preparation for Transplantation of Fecal Microbiota for Recurrent Clostridium difficile Infection , 2012, The American Journal of Gastroenterology.

[61]  R. Siebert,et al.  Microbial Exposure During Early Life Has Persistent Effects on Natural Killer T Cell Function , 2012, Science.

[62]  T. Borody,et al.  Fecal microbiota transplantation and emerging applications , 2012, Nature Reviews Gastroenterology &Hepatology.

[63]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[64]  J. Bakken,et al.  Treating Clostridium difficile infection with fecal microbiota transplantation. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[65]  D. Livert,et al.  Predictors of Fatal Outcome after Colectomy for Fulminant Clostridium difficile Colitis: A 10-Year Experience , 2011, The American surgeon.

[66]  J. Ballard,et al.  Clostridium difficile infection , 2014, Autopsy & case reports.

[67]  Yan Li,et al.  Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. , 2010, Gastroenterology.

[68]  A. Sonenshein,et al.  Inhibiting the Initiation of Clostridium difficile Spore Germination using Analogs of Chenodeoxycholic Acid, a Bile Acid , 2010, Journal of bacteriology.

[69]  T. Lamont,et al.  Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. , 2010, Journal of pediatric gastroenterology and nutrition.

[70]  J. Vederas,et al.  Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile , 2010, Proceedings of the National Academy of Sciences.

[71]  D. Gerding,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) , 2010, Infection Control & Hospital Epidemiology.

[72]  Mark A. Miller.  The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. , 2009, Anaerobe.

[73]  J. Heap,et al.  SleC Is Essential for Germination of Clostridium difficile Spores in Nutrient-Rich Medium Supplemented with the Bile Salt Taurocholate , 2009, Journal of bacteriology.

[74]  A. Zychlinsky,et al.  NETs: a new strategy for using old weapons. , 2009, Trends in immunology.

[75]  Christopher T. Walsh,et al.  Antibiotics for Emerging Pathogens , 2009, Science.

[76]  J. Jansson,et al.  Changes in the Composition of the Human Fecal Microbiome After Bacteriotherapy for Recurrent Clostridium difficile-associated Diarrhea , 2009, Journal of clinical gastroenterology.

[77]  D. Gerding,et al.  Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. , 2009, Gastroenterology.

[78]  C. Kelly,et al.  Clostridium difficile--more difficult than ever. , 2008, The New England journal of medicine.

[79]  A. Hofmann,et al.  Bile Acids: Chemistry, Pathochemistry, Biology, Pathobiology, and Therapeutics , 2008, Cellular and Molecular Life Sciences.

[80]  D. Antonopoulos,et al.  Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. , 2008, The Journal of infectious diseases.

[81]  Carlene A. Muto,et al.  Treatment of Clostridium difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[82]  D. Relman,et al.  An ecological and evolutionary perspective on human–microbe mutualism and disease , 2007, Nature.

[83]  C. Hill,et al.  Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. , 2007, Journal of medical microbiology.

[84]  O. Lesur,et al.  Impact of Emergency Colectomy on Survival of Patients With Fulminant Clostridium difficile Colitis During an Epidemic Caused by a Hypervirulent Strain , 2007, Annals of surgery.

[85]  J. Ballard,et al.  Clostridium difficile Toxins: Mechanism of Action and Role in Disease , 2005, Clinical Microbiology Reviews.

[86]  F. Bäckhed,et al.  Host-Bacterial Mutualism in the Human Intestine , 2005, Science.

[87]  A. Zychlinsky,et al.  Neutrophil Extracellular Traps Kill Bacteria , 2004, Science.

[88]  A. Pinetti,et al.  Influence of newly synthesized cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption , 2003, Hepatology.

[89]  R. P. Ross,et al.  Preservation and fermentation: past, present and future. , 2002, International journal of food microbiology.

[90]  Lynne V McFarland,et al.  Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease , 2002, American Journal of Gastroenterology.

[91]  R. Lenski,et al.  Chemical warfare from an ecological perspective , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[92]  C. Pothoulakis,et al.  Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[93]  B. de Kruijff,et al.  The lantibiotic nisin, a special case or not? , 1999, Biochimica et biophysica acta.

[94]  R. P. Ross,et al.  Lacticin 3147, a Broad-Spectrum Bacteriocin Which Selectively Dissipates the Membrane Potential , 1998, Applied and Environmental Microbiology.

[95]  C. Steer,et al.  The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. , 1995, Gastroenterology.

[96]  N. Abate,et al.  Regulation of bile acid synthesis in humans: Effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7α‐hydroxylation rates in vivo , 1991, Hepatology.

[97]  K. Einarsson,et al.  Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients. , 1990, Journal of lipid research.

[98]  K. Wilson,et al.  Role of competition for nutrients in suppression of Clostridium difficile by the colonic microflora , 1988, Infection and immunity.

[99]  K. Wilson.  Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination , 1983, Journal of clinical microbiology.

[100]  D. Youngs,et al.  Randomized controlled trial of colestipol in antibiotic‐associated colitis , 1982, The British journal of surgery.

[101]  H. Mekhjian,et al.  Colonic absorption of unconjugated bile acids , 1979, Digestive Diseases and Sciences.

[102]  M. Garnick,et al.  Sex differences in the size of bile acid pools. , 1978, Metabolism: clinical and experimental.

[103]  C L Oakley,et al.  Clostridium difficile: isolation and characteristics. , 1976, Journal of medical microbiology.

[104]  H. Mangurten,et al.  A 10-Year Experience , 2017 .

[105]  J. Meek,et al.  Burden of Clostridium difficile infection in the United States. , 2015, The New England journal of medicine.

[106]  T. Wilt,et al.  Fecal Microbiota Transplantation for Clostridium Difficile Infection: A Systematic Review of the Evidence , 2014 .

[107]  E. Feuille.  The Antibacterial Lectin RegIII-Gamma Promotes the Spatial Segregation of Microbiota and Host in the Intestine , 2012 .

[108]  D. Holdstock.  Past, present--and future? , 2005, Medicine, conflict, and survival.

[109]  M. Fingerman,et al.  Immunobiology and pathology , 2000 .

[110]  J D Taulbee,et al.  Age and diet effects on fecal bile acids in infants. , 1988, Journal of pediatric gastroenterology and nutrition.

[111]  Hammons Jl,et al.  Age and diet effects on fecal bile acids in infants. , 1988 .

[112]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.

[113]  東京物理學校,et al.  理學 : The science , 1946 .